Theralase Technologies Inc
Company Profile
Business description
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
Contact
41 Hollinger Road
TorontoONM4B 3G4
CANT: +1 416 699-5273
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
14
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
stocks
World’s largest miner overvalued after solid quarter
stocks
Hidden value in an expensive ASX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.20 | 45.20 | -0.50% |
| CAC 40 | 8,156.43 | 79.28 | -0.96% |
| DAX 40 | 24,194.90 | 75.97 | -0.31% |
| Dow JONES (US) | 49,490.03 | 340.65 | 0.69% |
| FTSE 100 | 10,476.46 | 21.63 | -0.21% |
| HKSE | 25,888.82 | 274.42 | -1.05% |
| NASDAQ | 24,657.57 | 397.60 | 1.64% |
| Nikkei 225 | 59,058.08 | 527.78 | -0.89% |
| NZX 50 Index | 12,884.93 | 60.67 | -0.47% |
| S&P 500 | 7,137.90 | 73.89 | 1.05% |
| S&P/ASX 200 | 8,776.10 | 43.40 | -0.49% |
| SSE Composite Index | 4,086.79 | 19.47 | -0.47% |